SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Concord Medical Services Holdings Ltd – ‘20-F’ for 12/31/19 – ‘R22’

On:  Thursday, 4/30/20, at 4:38pm ET   ·   For:  12/31/19   ·   Accession #:  1104659-20-54484   ·   File #:  1-34563

Previous ‘20-F’:  ‘20-F’ on 4/30/19 for 12/31/18   ·   Next:  ‘20-F’ on 10/15/21 for 12/31/20   ·   Latest:  ‘20-F’ on 4/19/24 for 12/31/23   ·   4 References:   

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 4/30/20  Concord Medical Svcs Holdings Ltd 20-F       12/31/19  164:22M                                    Toppan Merrill/FA

Annual Report by a Foreign Non-Canadian Issuer   —   Form 20-F   —   Sect. 13 / 15(d) – SEA’34
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 20-F        Annual Report by a Foreign Non-Canadian Issuer      HTML   1.69M 
 2: EX-2.4      Plan of Acquisition, Reorganization, Arrangement,   HTML    102K 
                Liquidation or Succession                                        
 3: EX-8.1      Opinion of Counsel re: Tax Matters                  HTML     44K 
 6: EX-13.1     Annual or Quarterly Report to Security Holders      HTML     44K 
 7: EX-13.2     Annual or Quarterly Report to Security Holders      HTML     43K 
 4: EX-12.1     Statement re: Computation of Ratios                 HTML     49K 
 5: EX-12.2     Statement re: Computation of Ratios                 HTML     49K 
 8: EX-15.1     Letter re: Unaudited Interim Financial Info         HTML     42K 
69: R1          Document and Entity Information                     HTML     82K 
135: R2          Consolidated Balance Sheets                         HTML    199K  
115: R3          Consolidated Balance Sheets (Parenthetical)         HTML     85K  
21: R4          Consolidated Statements of Comprehensive Loss       HTML    145K 
74: R5          Consolidated Statements of Comprehensive Loss       HTML     48K 
                (Parenthetical)                                                  
140: R6          Consolidated Statements of Cash Flows               HTML    248K  
120: R7          Consolidated Statements of Shareholders' Equity     HTML    112K  
15: R8          Organization and Basis of Presentation              HTML    349K 
75: R9          Summary of Significant Accounting Policies          HTML    220K 
18: R10         Concentration of Risks                              HTML     55K 
71: R11         Acquisitions and Disposals                          HTML    180K 
136: R12         Short Term Investment                               HTML     47K  
116: R13         Accounts Receivable                                 HTML     97K  
20: R14         Prepayments and Other Current Assets                HTML    115K 
73: R15         Inventories                                         HTML     75K 
138: R16         Assets Held for Sale                                HTML     46K  
118: R17         Property, Plant and Equipment, Net                  HTML     86K  
16: R18         Lease                                               HTML    299K 
76: R19         Goodwill                                            HTML     71K 
158: R20         Intangible Assets, Net                              HTML    189K  
103: R21         Deposits for Non-Current Assets                     HTML     64K  
47: R22         Long-Term Investments                               HTML    131K 
65: R23         Other Non-Current Assets                            HTML     71K 
160: R24         Accrued Expenses and Other Liabilities              HTML     84K  
105: R25         Shareholders' Equity                                HTML     49K  
49: R26         Bank and Other Borrowings                           HTML     92K 
67: R27         Restricted Net Assets                               HTML     49K 
161: R28         Taxation                                            HTML    302K  
101: R29         Share-Based Awards                                  HTML    179K  
112: R30         Revenue                                             HTML    111K  
132: R31         Related Party Transactions                          HTML    265K  
80: R32         Employee Defined Contribution Plan                  HTML     48K 
26: R33         Commitments and Contingencies                       HTML     47K 
110: R34         Segment Reporting                                   HTML    168K  
130: R35         Loss Per Share                                      HTML    121K  
78: R36         Fair Value Measurements                             HTML    165K 
24: R37         Parent Company Only Condensed Financial             HTML    232K 
                Information                                                      
114: R38         Subsequent Events                                   HTML     47K  
129: R39         Summary of Significant Accounting Policies          HTML    318K  
                (Policies)                                                       
98: R40         Organization and Basis of Presentation (Tables)     HTML    338K 
155: R41         Summary of Significant Accounting Policies          HTML    203K  
                (Tables)                                                         
55: R42         Acquisitions and Disposals (Tables)                 HTML    182K 
38: R43         Accounts Receivable (Tables)                        HTML     96K 
96: R44         Prepayments and Other Current Assets (Tables)       HTML    115K 
153: R45         Inventories (Tables)                                HTML     76K  
53: R46         Property, Plant and Equipment, Net (Tables)         HTML     82K 
36: R47         Lease (Tables)                                      HTML    307K 
100: R48         Goodwill (Tables)                                   HTML     70K  
152: R49         Intangible Assets, Net (Tables)                     HTML    192K  
145: R50         Deposits for Non-Current Assets (Tables)            HTML     63K  
127: R51         Long-Term Investments (Tables)                      HTML    132K  
27: R52         Other Non-Current Assets (Tables)                   HTML     71K 
82: R53         Accrued Expenses and Other Liabilities (Tables)     HTML     84K 
146: R54         Bank and Other Borrowings (Tables)                  HTML     93K  
128: R55         Taxation (Tables)                                   HTML    302K  
28: R56         Share-Based Awards (Tables)                         HTML    181K 
84: R57         Revenue (Tables)                                    HTML    110K 
147: R58         Related Party Transactions (Tables)                 HTML    251K  
126: R59         Segment Reporting (Tables)                          HTML    173K  
41: R60         Loss Per Share (Tables)                             HTML    121K 
56: R61         Fair Value Measurements (Tables)                    HTML    160K 
148: R62         Parent Company Only Condensed Financial             HTML    233K  
                Information (Tables)                                             
91: R63         Organization and Basis of Presentation (Schedule    HTML    132K 
                of Subsidiaries) (Details)                                       
44: R64         Organization and Basis of Presentation (Schedule    HTML    163K 
                of financial information) (Details)                              
59: R65         Organization and Basis of Presentation (Narrative)  HTML    280K 
                (Details)                                                        
151: R66         Summary of Significant Accounting Policies          HTML     57K  
                (Schedule of Information Relating to Property,                   
                Plant and Equipment) (Details)                                   
95: R67         Summary of Significant Accounting Policies          HTML     60K 
                (Schedule of estimated useful life for the                       
                intangible assets) (Details)                                     
39: R68         Summary of Significant Accounting Policies          HTML     48K 
                (Summary of revenue recognized) (Details)                        
60: R69         Summary of Significant Accounting Policies          HTML     62K 
                (Adoption of ASU) (Details)                                      
90: R70         Summary of Significant Accounting Policies -        HTML     71K 
                Adoption of ASU-842 (Details)                                    
32: R71         Summary of Significant Accounting Policies          HTML    101K 
                (Narrative) (Details)                                            
125: R72         Concentration of Risks (Narrative) (Details)        HTML     57K  
144: R73         Acquisitions and Disposals (Schedule of Assets and  HTML     62K  
                Liabilities of Beijing Century Friendship and                    
                Bpmc) (Details)                                                  
87: R74         Acquisitions and Disposals (Schedule of Gain        HTML     48K 
                Realized on Deemed Disposal) (Details)                           
29: R75         Acquisitions and Disposals (Schedule of purchase    HTML    101K 
                price as of the date of acquisition) (Details)                   
122: R76         Acquisitions and Disposals (Schedule of Pro forma   HTML     53K  
                Results) (Details)                                               
141: R77         Acquisitions and Disposals (Schedule of Actual      HTML     53K  
                Results from Acquisition Date) (Details)                         
86: R78         Acquisitions and Disposals (Narrative) (Details)    HTML    208K 
34: R79         Short Term Investment (Debt Investment) (Details)   HTML     50K 
89: R80         Accounts Receivable (Schedule of Accounts           HTML     68K 
                Receivable) (Details)                                            
31: R81         Accounts Receivable (Narrative) (Details)           HTML     45K 
124: R82         Prepayments and Other Current Assets (Schedule of   HTML     75K  
                Prepayments and Other Current Assets) (Details)                  
143: R83         Prepayments and Other Current Assets (Narrative)    HTML     61K  
                (Details)                                                        
88: R84         Inventories (Schedule of Inventory) (Details)       HTML     59K 
30: R85         Assets Held for Sale (Narrative) (Details)          HTML     45K 
123: R86         Property, Plant and Equipment, Net (Schedule of     HTML     72K  
                Property Plant and Equipment Net) (Details)                      
142: R87         Property, Plant and Equipment, Net - (Narrative)    HTML     67K  
                (Details)                                                        
85: R88         Lease (Narrative) (Details)                         HTML     88K 
33: R89         Lease (Lease receivables) (Details)                 HTML     54K 
42: R90         Lease (Net investment in direct financing leases)   HTML     56K 
                (Details)                                                        
57: R91         Lease (Summary of non-cancelable direct financing   HTML     55K 
                leases) (Details)                                                
149: R92         Lease (Schedule of Prepaid Land Lease Payments)     HTML     56K  
                (Details)                                                        
93: R93         Lease (Other operating leases) (Details)            HTML     50K 
43: R94         Lease (Other information) (Details)                 HTML     53K 
58: R95         Lease (Summary of future lease payments) (Details)  HTML     62K 
150: R96         Lease (Schedule of Estimated Annual Amortization    HTML     51K  
                Expenses) (Details)                                              
94: R97         Lease (Lease income) (Details)                      HTML     57K 
40: R98         Lease ( Schedule of Non-cancellable Operating       HTML     56K 
                Lease Payment) (Details)                                         
61: R99         Goodwill (Carrying Amount) (Details)                HTML     48K 
162: R100        Goodwill (Narrative) (Details)                      HTML     49K  
108: R101        Intangible Assets, Net (Schedule of Acquired        HTML    101K  
                Intangible Assets) (Details)                                     
45: R102        Intangible Assets, Net (Schedule of Estimated       HTML     55K 
                Annual Amortization Expenses) (Details)                          
62: R103        Intangible Assets, Net (Narrative) (Details)        HTML     52K 
163: R104        Deposits for Non-Current Assets (Schedule of        HTML     50K  
                Deposits for Non-Current Assets) (Details)                       
109: R105        Deposits for Non-Current Assets (Schedule of        HTML     59K  
                Deposits for Non-Current Assets) (Narrative)                     
                (Details)                                                        
46: R106        Long-Term Investments (Details)                     HTML     51K 
63: R107        Long-Term Investments (Details 1)                   HTML     48K 
164: R108        Long-Term Investments (Schedule of Equity Method    HTML     69K  
                Investments) (Details 2)                                         
107: R109        Long-Term Investments (Narrative) (Details)         HTML    193K  
119: R110        Other Non-Current Assets (Schedule of Other         HTML     56K  
                Non-Current Assets) (Details)                                    
139: R111        Other Non-Current Assets (Narrative) (Details)      HTML     46K  
72: R112        Accrued Expenses and Other Liabilities (Schedule    HTML     72K 
                of Accrued Expenses and Other Liabilities)                       
                (Details)                                                        
19: R113        Shareholders' Equity (Narrative) (Details)          HTML     72K 
117: R114        Bank and Other Borrowings (Schedule of Bank and     HTML     55K  
                Other Borrowings) (Details)                                      
137: R115        Bank and Other Borrowings (Schedule of Maturities   HTML     62K  
                of Long-Term and Other Debt) (Details)                           
70: R116        Bank and Other Borrowings (Narrative) (Details)     HTML     84K 
17: R117        Restricted Net Assets (Narrative) (Details)         HTML     54K 
121: R118        Taxation (Narrative) (Details)                      HTML    100K  
134: R119        Taxation (Schedule of (Loss) Income from            HTML     51K  
                Continuing Operations Before Income Taxes)                       
                (Details)                                                        
68: R120        Taxation (Schedule of Income Tax Expense from       HTML     53K 
                Continuing Operations) (Details)                                 
50: R121        Taxation (Reconciliation of Differences Between     HTML     82K 
                Statutory Tax Rate and Effective Tax Rate)                       
                (Details)                                                        
104: R122        Taxation (Reconciliation of Differences Between     HTML     46K  
                Statutory Tax Rate and Effective Tax Rate)                       
                (Parenthetical) (Details)                                        
159: R123        Taxation (Schedule of Deferred Taxes) (Details)     HTML    120K  
66: R124        Taxation (Schedule of Movement of Valuation         HTML     47K 
                Allowance) (Details)                                             
48: R125        Taxation (Reconciliation of Accrued Unrecognized    HTML     58K 
                Tax Positions) (Details)                                         
102: R126        Share-Based Awards (Narrative) (Details)            HTML     68K  
157: R127        Share-Based Awards (Schedule of Assumptions Used)   HTML     52K  
                (Details)                                                        
64: R128        Share-Based Awards (Schedule of Stock Options)      HTML     91K 
                (Details)                                                        
51: R129        Share-Based Awards (Summary of Restricted Shares)   HTML    112K 
                (Details)                                                        
23: R130        Share-Based Awards (Schedule of Share-Based         HTML     52K 
                Compensation Expense) (Details)                                  
77: R131        Revenue (Details)                                   HTML     73K 
131: R132        Related Party Transactions (Schedule of Related     HTML    100K  
                Party Transactions) (Details)                                    
111: R133        Related Party Transactions (Schedule of Related     HTML     74K  
                Party Balances) (Details)                                        
25: R134        Employee Defined Contribution Plan (Narrative)      HTML     51K 
                (Details)                                                        
79: R135        Commitments and Contingencies (Narrative)           HTML     49K 
                (Details)                                                        
133: R136        Segment Reporting (Narrative) (Details)             HTML     50K  
113: R137        Segment Reporting (Schedule of Segment              HTML     67K  
                Information) (Details)                                           
22: R138        Segment Reporting (Schdeule of Net Revenue by       HTML     51K 
                Country based upon Sales Location that                           
                Predominately represents Customer Location)                      
                (Details)                                                        
81: R139        Segment Reporting (Schdeule of Total Long-Lived     HTML     50K 
                Assets excluding Financial Instruments, Intangible               
                Assets and Deferred Tax Assets by Country)                       
                (Details)                                                        
35: R140        Loss Per Share (Schedule of Basic and Diluted       HTML     69K 
                Income Per Share) (Details)                                      
52: R141        Fair Value Measurements (Schedule of Fair Value     HTML     68K 
                Measurements for Each Class of Assets on                         
                Nonrecurring Basis) (Details)                                    
154: R142        Fair Value Measurements (Narrative) (Details)       HTML     51K  
97: R143        Parent Company Only Condensed Financial             HTML    121K 
                Information (Condensed balance Sheets) (Details)                 
37: R144        Parent Company Only Condensed Financial             HTML     67K 
                Information (Condensed balance Sheets)                           
                (Parenthetical) (Details)                                        
54: R145        Parent Company Only Condensed Financial             HTML     90K 
                Information (Condensed statements of comprehensive               
                loss) (Details)                                                  
156: R146        Parent Company Only Condensed Financial             HTML     64K  
                Information (Condensed statements of cash flows)                 
                (Details)                                                        
99: R147        Subsequent Events (Narrative) (Details)             HTML     57K 
83: XML         IDEA XML File -- Filing Summary                      XML    327K 
106: EXCEL       IDEA Workbook of Financial Reports                  XLSX    210K  
 9: EX-101.INS  XBRL Instance -- ccm-20191231                        XML   7.89M 
11: EX-101.CAL  XBRL Calculations -- ccm-20191231_cal                XML    369K 
12: EX-101.DEF  XBRL Definitions -- ccm-20191231_def                 XML   1.28M 
13: EX-101.LAB  XBRL Labels -- ccm-20191231_lab                      XML   2.38M 
14: EX-101.PRE  XBRL Presentations -- ccm-20191231_pre               XML   2.13M 
10: EX-101.SCH  XBRL Schema -- ccm-20191231                          XSD    410K 
92: ZIP         XBRL Zipped Folder -- 0001104659-20-054484-xbrl      Zip    441K 


‘R22’   —   Long-Term Investments


This is an IDEA Financial Report.  [ Alternative Formats ]



 
v3.20.1
LONG-TERM INVESTMENTS
12 Months Ended
LONG-TERM INVESTMENTS  
LONG-TERM INVESTMENTS

15.  LONG-TERM INVESTMENTS

Long-term investments held by the Group consisted of the following:

 

 

 

 

 

 

 

 

 

 

As at December 31, 

 

 

2018

 

2019

 

2019

 

    

RMB

    

RMB

    

US$

Equity investments without readily determinable fair value

 

22,160

 

22,160

 

3,183

Equity method investments

 

366,204

 

42,788

 

6,146

Less: Impairment loss

 

 —

 

 —

 

 —

Total

 

388,364

 

64,948

 

9,329

 

Equity investments without readily determinable fair value:

 

 

 

 

 

 

 

 

 

 

 

 

 

Equity interest owned by the

 

 

 

 

 

Group

 

 

 

 

 

As at December 31, 

 

 

 

Note

 

2018

 

2019

 

Allcure Information

    

i)

    

9.6

%  

9.6

%

 

i)

20% equity interest of Allcure Information was obtained through the disposal of Allcure Medical Technology Co., Ltd. (“JWYK”) in 2015. During year ended December 31, 2018 Allcure Information issued new shares to other investors and diluted the share ownership of the Group to 9.6%. The price of newly issued shares is not considered an observable price change because they are not a similar investment of JWYK held by the Group due to the different rights and obligations associated with the investments. As at year ended December 31, 2019, the share ownership of the Group remained 9.6%. As of December 31, 2018 and 2019, no impairment was recorded for the investment.

The Group did not record any unrealized gains (upward adjustments) and losses (downward adjustments and impairment) for equity investments without readily determinable fair values for the years presented.

 

Equity method investments:

 

 

 

 

 

 

 

 

 

 

 

Equity interest owned by the

 

 

 

 

Group

 

 

 

 

As at December 31, 

 

 

 

Notes

2018

 

2019

 

Xi’an JiangyuanAndike Ltd. (“JYADK”)

    

 

29.70

%  

29.70

%  

PTC

 

i)

59.51

%  

59.51

%

Suzhou Shengshan Huiying Venture Capital Investment LLP. (“Suzhou Shengshan”)

 

ii)

5.41

%  

5.15

%

Suzhou Chorus Medical Technologies Co., Ltd. (“Suzhou Chorus”)

 

iii)

36.00

%  

 —

 

Shanghai Meizhong Jiahe Imaging Diagnostic Center Co., Ltd. ("SH MZJH")

 

iv)

43.23

%  

 —

 

Shanghai Rongchi Medical Management Co., Ltd. ("SH Rongchi")

 

iv)

24.40

%  

 —

 

Tianjin Jiatai Enterprise Management Center (Limited Partnership) ("Tianjin Jiatai")

 

iv)

22.82

%  

 —

 

Wuxi Meizhong Jiahe Cancer Center (“Wuxi MZJH”)

 

v)

10.00

%  

 —

 

DTAP @ Adam Road PTE.LTD. (“DTAP”)

 

vi)

49.00

%  

 —

 

 

i)

On December 28, 2012, the Group acquired 44.55% limited partner interests of PTC, a limited partnership in Texas, U.S.A., and 45% legal interest of PTC GP Management LLC, a limited liability company registered in Texas, U.S.A and the sole general partner of PTC with 1% interest of PTC, with a consideration of RMB201,176 in cash. On July 31, 2015, the Group acquired additional 14.34% limited partner interests of PTC and additional 17.07% legal interest of PTC GP Management LLC, with a consideration of RMB30,063 in cash. After the additional investments, the Group owned 59.51% interests of PTC which ultimately holds 45.41% legal ownership interests of the University of Texas MD Anderson Cancer Center Proton Therapy Center (“MDA Proton”), a proton treatment center in Texas, U.S.A.

In accordance with PTC GP Management LLC’s regulation, the Group is only entitled to designate two out of the five managers and simply majority (more than 50%) amongst the managers is required to pass any resolution. Furthermore, the regulation can only be amended at the request by managers or super majority (more than 2/3) of member interest. Thus, the Group is not able to control PTC GP Management LLC.

According to the partnership agreements, the Group has significant influence over PTC which can demonstrate control over MDA Proton by acting as the sole general partner. On November 29, 2018, MDA Proton reached an agreement with University of Texas MD Anderson Cancer Center ("UTMDACC") to sell all its assets and liabilities to UTMDACC as well as terminating management service agreement between MDA Proton and PTC. Before the transaction, the Group accounts for its investment in PTC, and ultimately MDA Proton, under the equity method of accounting. The Group’s share of the net profit or loss of PTC, after accounting for the effect of the difference between the cost basis of the equity method investment and the underlying assets of the investee, was a gain of RMB17,697,  RMB509 and nil for the years ended December 31, 2017, 2018 and 2019 respectively. Total cash distribution received by the Group from PTC was RMB6,227,  RMB11,626 and nil for the years ended December 31, 2017, 2018 and 2019, respectively.

The Group received the first installment of consideration RMB212,855 from PTC on dissolution between MDA Proton and PTC, leading to the disposal gain of RMB48,019 in 2018. The Group received the second and the third installments totaling RMB6,779 (US$973) in 2019 and the carrying amount of the equity investment remained RMB31,497 and RMB24,718 (US$3,551) as of December 31, 2018 and 2019.

ii)

In 2017, JKSY, a subsidiary of the Group, entered into a partnership agreement to subscribe for 8.13% interest in Suzhou Shengshan, a partnership engaged in equity and capital investment, with a subscription amount of RMB10,000. In 2018, with the subscribed capital injection from new investors, the equity interest JKSY shared in Suzhou Shengshan should be diluted to 4.57%. As the injection was only partially completed, the actual equity interest shared in Suzhou Shengshan was diluted to 5.41% as of December 31, 2018. In 2019, with the subscribed capital injection from new investors, the actual equity interest shared in Suzhou Shengshan was further diluted to 5.15% as of December 31, 2019. According to the partnership agreement, JKSY acts as a limited partner and has significant influence over Suzhou Shengshan's daily operation.

iii)

In 2015, the Group entered into a share transfer agreement with JWYK, which was controlled by one of the Group's directors. Pursuant to the agreements, the Group would sell 36% equity interest in Suzhou Chorus at a consideration of RMB4,320 to JWYK. The consideration was received by the Group in April 2016. The disposal of Suzhou Chorus was completed in 2019.

iv)

During 2019, Tianjin Jiatai made total capital injections amouting to RMB34,540 to SH MZJH, leading to Tianjin Jiatai’s equity interest on SH MZJH from 56.77% to 78.34%. On November 13, 2019, Guofu Huimei entered into agreements with ZR Guofu, pursuant to which ZR Guofu would withdraw its investment of 77.18% equity interests in Tianjin Jiatai at a consideration of RMB421,730 (US$60,578). Upon the completion of the transaction, Tianjin Jiatai and its subsidiaries, SH MZJH, Heze MZJH, SH Rongchi, Wuxi MZJH and Oriental became subsidiaries of the Group (note 4).

v)

On July 22, 2019, Wuxi Concord, a wholly-owned subsidiary of the Group, entered into an agreement with Tianjin Jiatai, to purchase all its 90% equity interests in Wuxi MZJH at a consideration of RMB27,000. After the acquisition, Wuxi MZJH became a wholly-owned subsidiary of the Group. On August 23, 2019, Wuxi Concord further injected capital of RMB82,110 to Wuxi MZJH.

vi)

In December 2018, DTAP was set up and registered in Singapore by CHS and Republic Healthcare Holdings PTE.LTD (“RHHPL”), a third party of the Group. CHS subscribed to inject SG$0.49 to share 49% equity of DTAP, and accounted for the investment as joint venture according to the cooperation agreement. On July 11, 2019, CHS and RHHPL consented to discontinue the joint venture agreement and CHS’s subscription of 49% shares has transferred to RHHPL at SG$0.49 in the capital of DTAP. DTAP had no substantial business from its inception to discontinuance.

 


Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘20-F’ Filing    Date    Other Filings
Filed on:4/30/20
For Period end:12/31/19
11/13/19
8/23/19
7/22/19
7/11/19
12/31/1820-F
11/29/18
12/31/1720-F
7/31/15
12/28/12
 List all Filings 


4 Subsequent Filings that Reference this Filing

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 4/19/24  Concord Medical Svcs Holdings Ltd 20-F       12/31/23  166:21M                                    Toppan Merrill/FA
 4/19/23  Concord Medical Svcs Holdings Ltd 20-F       12/31/22  170:22M                                    Toppan Merrill/FA2
 4/29/22  Concord Medical Svcs Holdings Ltd 20-F       12/31/21  170:23M                                    Toppan Merrill/FA2
10/15/21  Concord Medical Svcs Holdings Ltd 20-F       12/31/20  166:22M                                    Toppan Merrill/FA
Top
Filing Submission 0001104659-20-054484   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Wed., May 15, 2:37:51.1pm ET